BioInformant

Your Global Leader in Stem Cell Market Research

Home » cord blood » Page 2

Cord Blood Registry (CBR®) by Generate Life Sciences Partners with NantKwest to Develop Covid-19 Treatment

By Leave a Comment

CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy

Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natural killer cell-based immunotherapy company, announced a collaboration to develop a COVID-19 treatment leveraging newborn stem cells. CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cells (MSCs) to NantKwest for efficient and robust expansion utilizing their proprietary modular, closed bioreactor system from NantKwest affiliate ImmunityBio, Inc. [Read more…]

CBR Announces New Pediatric Genetic Screening Test in Collaboration with Sema4

By Leave a Comment

Sema4 collaborated with CBR to launch ReadyGen™, a genetic screening test that analyzes a child’s DNA for 200+ conditions.

LOS ANGELES, Nov. 15, 2019 — CBR, the global leader in newborn stem cell banking, has announced a new genetic service developed over the past couple of years as part of a strategic alliance with Sema4. As a patient-centered health intelligence company and leading innovator within the genomic testing industry, Sema4 collaborated with CBR to launch ReadyGen™, a highly accurate genetic screening test that analyzes a child’s DNA for more than 200 conditions that can affect children before the age of 10. [Read more…]

CBR to Acquire Natera’s Evercord™ Cord Blood Business for an Undisclosed Sum

By Leave a Comment

Cord Blood Registry (CBR), a California Cryobank Life Sciences company, has announced it will acquire Natera’s Evercord™ cord blood business for an undisclosed sum. CBR is the largest newborn stem cell collection and storage company within the United States with more than 875,000 stem cell samples in storage. Natera is a publicly listed company (NASDAQ: NTRA) that specializes in genetic testing services. [Read more…]

Will I See You at Phacilitate Leaders World 2020 (Psst, Get 10% Off)

By 2 Comments

Advanced therapy companies have been rapidly populating over the past few years, making it a high-value, fast-growth industry. Key drivers include high rates of clinical trials, accelerated pathways for product approvals, new technologies to support cell and gene therapy manufacturing, and the potential for advanced therapies to revolutionize healthcare.

Stem Cell Industry Growth

Stem cell treatments are one of several segments that compose the advanced therapies industry, which includes but is not limited to cell therapy, gene therapy, and tissue engineering applications.

Stem cells have gained tremendous momentum over the last decade. As of November 2019, stem cell scientific publications have reached over 364,930 worldwide, with 25,000+ now being published per year.

Number of Stem Cell Scientific Publications Worldwide

For stem cell clinical trials, 7,400+ have been registered on ClinicalTrials.gov. Because this registry includes approximately 3/4ths of clinical trials worldwide, the total number of stem cell clinical trials worldwide is estimated to be approaching 10,000.

[Read more…]

BioInformant's World-Class Clients